Drug for Advanced Breast Cancer Promising
Posted on: Friday, 2 November 2007, 15:00 CDT
A drug that has shown promise in treating sarcoma, lung and brain cancers may also be effective in treating breast cancer, a U.S. study found.
Researchers at the Mayo Clinic in Rochester, Minn., say that Panzem, or 2-methoxyestradiol, also known as 2ME2, is in clinical trials by other researchers as a treatment for various cancers.
Corresponding author of the study Muzaffer Cicek, a cell biologist in endocrine research at the Mayo Clinic, said 2ME2 is derived from estrogen and works by suppressing tumor growth and blocking the formation of new blood vessels that feed tumors.
2ME2 could benefit patients because this single drug essentially combines the effects of chemotherapy, which destroys cancer cells, and antiangiogenesis drugs, which destroy blood vessels that feed tumors, Cicek said in a statement.
The study, based on mouse models and published in Cancer Research, described 2ME2 as an attractive candidate for controlling tumor growth, metastasis to bone and bone disorders, such as osteolysis caused by the spread of breast cancer to bone.
The Mayo Clinic study delivers 2ME2 by injection and in a lower dose -- eight times lower than the comparable oral version used in mouse models.
Source: United Press International
Related Articles
- GTx Announces Investigational Ostarine(TM) (MK-2866) Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial
- New Cancer-Prevention Clinic to Open Friday
- FermaVir Announces FDA Response to Its Pre-IND Submission for Initial Bioavailability Studies in Human Clinical Trials of FV-100; Response Enables Company to Plan Clinical Development Program for Novel Antiviral Drug Candidate
- Cabrellis Pharmaceuticals Initiates Phase II Study of Calsed(TM) in Small Cell Lung Cancer; Additional Clinical Data Presented at ASCO Annual Meeting
- Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy Clinical Trials at 2006 ASCO Annual Meeting
- Prevalence of Vitamin D Inadequacy in Patients Attending a Metabolic Bone Clinic in Medway
- Clinical Trial for Pancreatic Cancer Opens at Mayo Clinic Using Tumor-Targeted Gene Therapy Vector
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
- UA, Tucson Women Have Role in Cancer/Bone Study
- Adoptive Immunotherapy of Prostate Cancer Bone Lesions Using Redirected Effector Lymphocytes
 |
 |
User Comments (0)
RSS Feeds